Exciting News! The AIM-HI Accelerator Fund is thrilled to announce 4 Semi-Finalists competing in our Women’s Venture Competition this year, selected from a pool of 58 applications submitted by women-led, early-stage oncology companies from 10 different countries!

Congratulations to these outstanding women entrepreneurs and their companies:

  • AOA Dx | Oriana Papin-Zoghbi | CEO & Co-Founder
  • ARMA Bio | Paraskevi Giannakakou, Ph.D. | CSO
  • HDAX Therapeutics | Nabanita Nawar, Ph.D. | CEO & Co-Founder
  • Utter Therapeutics | Deborah Charych, Ph.D. | CEO

The winning early-stage oncology company of 2024 Women’s Venture Competition will be eligible to receive investment from AIM-HI and co-investors, subject to due diligence, which will serve as early seed money for proof of concept and proof of value on the path to clinical trials and, eventually, to new effective therapeutics that could save patients’ lives.

We would like to extend our heartful thanks to the selection and judging committee members for their tremendous support of AIM-HI and invaluable contributions to empower women scientist-entrepreneurs in oncology.

Trying to promote the involvement of women in cancer biotech as entrepreneurs is a great cause, and we want to say thank you to all of our dear supporters for helping advance that cause.

FacebookLinkedInTwitterPinterestEmail

About the AIM-HI Accelerator Fund

The AIM-HI Accelerator Fund (AIM-HI) is a 501(c)(3) nonprofit organization established in 2019 with an initial capacity-building grant from the National Foundation for Cancer Research to accelerate the translation of cancer drug discoveries by investing in seed-stage oncology companies. AIM-HI Accelerator Fund bridges the gap between innovative cancer discoveries and high-impact cancer treatments and technologies and facilitates an ecosystem for early-stage companies and entrepreneurs. To learn more about the AIM-HI Accelerator Fund, visit AIM-HIAccelerator.org.

About the National Foundation for Cancer Research

The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and Attorney/Business Entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab with the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, prevention, and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields often overlooked by other major funding sources. With the support of more than 5.3 million individual donors over the last 50+ years, NFCR has provided more than $415 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant life-saving discoveries that benefit patients today.